Kleiner Perkins startup could spell new era for Amgen
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →The high-tech plumber: Sani-Tech West keeps big bio names flowing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen revenue up 9 percent
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”24-10-2011″ enddate=”24-04-2012″ width=”300″ height=”245″] Amgen’s total revenue shot up 9 percent during the first quarter of this year, the Thousand Oaks-based biotech giant said in an April 24 earnings report. The biotech company reported revenue of $4 billion, up from $3.7 billion in the first quarter of 2011. Total product Read More →
Read More →Putting cures on a strip: Startup makes medicines for the third world
An Oxnard-based startup puts medicines and nutritional supplements on easy-to-use, Listerine-like strips that dissolve in the mouth.
Read More →Amgen braces for biosimilars rules
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Brave new biotech: Camarillo startup launches first products
PBS Biotech, a Camarillo-based startup, is bringing its first products to market.
Read More →Amgen drug shows blockbuster promise
Putting test results behind the talk at its recent product pipeline review, Thousand Oaks-based Amgen on May 17 released promising results for the Xgeva variant of its potential blockbuster bone drug denosumab.
Read More →
Sponsored content:
2015-2016 Giving Guide
